Rivastigmine 24HR Patches

Contract SPE2D2-22-D-0147 was awarded by the Defense Logistics Agency Troop Support Medical Supply Chain to Mylan Pharmaceuticals Inc. on September 14, 2022, for the supply of Rivastigmine 24HR patches in three dosage strengths: 4.6mg, 9.5mg, and 13.3mg. The contract has a total estimated value of $10,967,220 over a five-year period, consisting of a base year and four option years. The agreement is managed as a commercial item acquisition under FAR Part 12 with FOB Destination terms. Recent modifications have exercised Option Year 1 and Option Year 2, with the latter effective from September 14, 2024, through September 13, 2025, and including a unit price increase to $38.04. The contract mandates strict adherence to pharmaceutical traceability and security standards, specifically incorporating the Drug Supply Chain Security Act (DSCSA) for barcode labeling and the Federal Acquisition Supply Chain Security Act (FASCSA). Labeling requirements specify the use of GSI-128, GSI DataBar, or UPC symbology to encode National Drug Codes, lot numbers, and expiration dates, maintaining an ANSI/ISO/IEC quality grade of C or better. Additionally, the contract has been modified to include prohibitions on the use of ByteDance covered applications and other cybersecurity-related restrictions. Performance is supported by Mylan Pharmaceuticals Inc. out of Morgantown, West Virginia, with administrative oversight provided by DLA Troop Support in Philadelphia, Pennsylvania.